Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
57.4 SEK | +1.41% | -3.37% | +71.86% |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
- The company's profit outlook over the next few years is a strong asset.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
Weaknesses
- The company's enterprise value to sales, at 3.98 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- Over the past four months, analysts' average price target has been revised downwards significantly.
Ratings chart - Surperformance
Sector: Drug Retailers
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+71.86% | 155M | - | ||
-55.19% | 10.1B | B- | ||
-46.55% | 8.81B | B | ||
-25.71% | 6.65B | B | ||
-4.16% | 6.45B | C+ | ||
+97.00% | 5.35B | C | ||
-2.77% | 4.63B | D- | ||
+8.08% | 4.6B | B | ||
-32.12% | 3.79B | C | ||
+7.14% | 3.13B | B |
Financials
Valuation
Momentum
Consensus
Business Predictability
- Stock Market
- Equities
- EQL Stock
- Ratings EQL Pharma AB